inotek_logo

Inotek’s glaucoma lead candidate falls at Phase 3 trial

pharmafile | January 4, 2017 | News story | Research and Development Glaucoma, inotek, inotek pharma 

Inotek Pharmaceutical announced that its lead candidate, trabodenoson, a drug designed to treat glaucoma, had failed to outperform placebos in a Phase 3 trial. The drug is designed to reduce fluid pressure in the eye of patient’s suffering from glaucoma and those suffering from ocular pressure. There is, at present, no cure for glaucoma and only medication that can manage the condition.

The results sheared over 60% from Inotek’s share price, after the results were released. The primary endpoint, to reduce intraocular pressure at 12 different time points across 3 months of trials, was not reached in 303 patients.

“The results of the MATrX-1 trial demonstrate that trabodenoson, operating through a novel mechanism of action, actively lowers IOP with a tolerability profile that, remarkably, was similar to that observed in the placebo arm,” commented Rudolf Baumgartner, MD, executive vice president and CMO of Inotek.

The drug is Inotek’s lead candidate and Baumbartner’s comments seem to attribute the blame for the failure upon an unusually strong placebo reaction. Inotek pointed towards the benefits of the 6% dose of the drug, which was showed some statistical superiority over the placebo but not at all endpoints. The company plans to wait on the full results to determine how “behaviour of the placebo arm” may have influenced the results of the trial. On the safety side, the drug did not demonstrate any significant events and only 4 patients (2.2%) discontinued the trial due to adverse effects.

Ben Hargreaves

Related Content

bham_uni

Birmingham research paves way for new anti-fibrotic glaucoma treatment

New research from the University of Birmingham has shown that a novel low molecular weight …

fda2outsideweb

Aerie’s glaucoma drug gets strong preliminary FDA opinion

In a preliminary review of the drug, the FDA has judged that Aerie Pharmaceutical’s experimental …

needles

Valeant receives complete response letter from FDA on glaucoma drug

Valeant Pharmaceuticals has announced that it has received a complete response letter from the FDA …

Latest content